// ── API Client ──────────────────────────────────────────────────────────────
const API = (() => {
const BASE = '/api';
const getToken = () => localStorage.getItem('peptideos_token');
const setToken = (t) => localStorage.setItem('peptideos_token', t);
const clearToken = () => localStorage.removeItem('peptideos_token');
async function req(method, path, body) {
const token = getToken();
const opts = {
method,
headers: {
'Content-Type': 'application/json',
...(token ? { 'Authorization': `Bearer ${token}` } : {})
}
};
if (body !== undefined) opts.body = JSON.stringify(body);
const res = await fetch(BASE + path, opts);
const data = await res.json().catch(() => ({}));
if (!res.ok) throw Object.assign(new Error(data.error || 'Request failed'), { status: res.status });
return data;
}
return {
get: (path) => req('GET', path),
post: (path, body) => req('POST', path, body),
put: (path, body) => req('PUT', path, body),
delete: (path, body) => req('DELETE', path, body),
setToken, clearToken, getToken
};
})();
// ── App State ────────────────────────────────────────────────────────────────
const App = (() => {
let _token = API.getToken();
let _email = localStorage.getItem('peptideos_email') || '';
let _theme = localStorage.getItem('peptideos_theme') || 'system';
let _data = { peptides: [], planner: [], vials: [], logs: [], settings: {}, vendors: [], prices: [], orders: [] };
function applyTheme(t) {
_theme = t;
localStorage.setItem('peptideos_theme', t);
if (t === 'system') document.body.removeAttribute('data-theme');
else document.body.setAttribute('data-theme', t);
}
function isLoggedIn() { return !!_token; }
async function login(email, password) {
const { token } = await API.post('/auth/login', { email, password });
_token = token; _email = email;
API.setToken(token);
localStorage.setItem('peptideos_email', email);
}
async function register(email, password) {
const { token } = await API.post('/auth/register', { email, password });
_token = token; _email = email;
API.setToken(token);
localStorage.setItem('peptideos_email', email);
}
async function logout() {
await API.post('/auth/logout').catch(() => {});
API.clearToken();
localStorage.removeItem('peptideos_email');
_token = null; _email = '';
_data = { peptides: [], planner: [], vials: [], logs: [], settings: {}, vendors: [], prices: [], orders: [] };
}
async function loadAll() {
let [peptides, planner, vials, logs, settings, vendors, prices, orders] = await Promise.all([
API.get('/peptides'),
API.get('/planner'),
API.get('/vials'),
API.get('/logs'),
API.get('/settings'),
API.get('/vendors'),
API.get('/prices'),
API.get('/orders')
]);
if (!peptides.length) {
await Promise.all(DEFAULT_PEPTIDES.map(name => API.post('/peptides', { name }).catch(() => {})));
peptides = await API.get('/peptides');
}
_data = { peptides, planner, vials, logs, settings, vendors, prices, orders };
applyTheme(settings.theme || 'system');
return _data;
}
return {
isLoggedIn, login, register, logout, loadAll, applyTheme,
getData: () => _data,
getEmail: () => _email,
getTheme: () => _theme
};
})();
// ── Tab Navigation ───────────────────────────────────────────────────────────
const Tabs = (() => {
let current = 'dashboard';
document.getElementById('navPill').addEventListener('click', (e) => {
const btn = e.target.closest('[data-tab]');
if (!btn) return;
switchTo(btn.dataset.tab);
});
function switchTo(tabId) {
current = tabId;
document.querySelectorAll('.nav-tab').forEach(b =>
b.classList.toggle('active', b.dataset.tab === tabId)
);
document.querySelectorAll('.tab-content').forEach(c =>
c.classList.toggle('active', c.id === tabId)
);
}
return { switchTo, current: () => current };
})();
// ── Boot ─────────────────────────────────────────────────────────────────────
(async function boot() {
const storedTheme = localStorage.getItem('peptideos_theme') || 'system';
if (storedTheme !== 'system') document.body.setAttribute('data-theme', storedTheme);
if (window.location.pathname === '/reset') {
document.getElementById('authScreen').style.display = 'flex';
renderAuth('reset');
return;
}
if (App.isLoggedIn()) {
try {
await App.loadAll();
showApp();
} catch (e) {
if (e.status === 401) { API.clearToken(); showAuth('login'); }
else showApp();
}
} else {
showAuth('login');
}
})();
function showApp() {
document.getElementById('authScreen').style.display = 'none';
document.getElementById('mainApp').style.display = 'block';
renderAllTabs();
}
function showAuth(mode) {
document.getElementById('authScreen').style.display = 'flex';
document.getElementById('mainApp').style.display = 'none';
renderAuth(mode);
}
function renderAllTabs() {
renderDashboard();
renderToday();
renderWeek();
renderLogDose();
renderHistory();
renderVials();
renderVendors();
renderPrices();
renderCalc();
renderLibrary();
renderSettings();
renderOrders();
}
// ── Shared Helpers ────────────────────────────────────────────────────────────
const DAYS = ['Sun','Mon','Tue','Wed','Thu','Fri','Sat'];
function pad2(n) { return String(n).padStart(2, '0'); }
function ymd(d) {
return `${d.getFullYear()}-${pad2(d.getMonth()+1)}-${pad2(d.getDate())}`;
}
function planMatched(plan, logs) {
return logs.some(l => {
if (l.peptide !== plan.peptide) return false;
if (l.route !== plan.route) return false;
if (l.dose_unit !== plan.unit) return false;
const ratio = Math.abs(parseFloat(l.dose_value) - parseFloat(plan.dose)) / (parseFloat(plan.dose) || 1);
return ratio <= 0.02;
});
}
// ── Constants ─────────────────────────────────────────────────────────────────
// Library v2 — 43 peptides — 2026-06-04
const PEPTIDE_HALFLIFE = {
'BPC-157': { halfLife: 4, notes: 'Short acting; split into AM/PM dosing for best results' },
'TB-500': { halfLife: 24, notes: 'Long-acting systemic; weekly or twice-weekly dosing common' },
'Ipamorelin': { halfLife: 2, notes: 'GHRP; pulse dose 2–3× daily, ideally fasted' },
'CJC-1295': { halfLife: 168, notes: 'Long-acting GHRH analogue with DAC; once weekly dosing' },
'Tesamorelin': { halfLife: 0.5, notes: 'Very short half-life; daily subcutaneous injection required' },
'Sermorelin': { halfLife: 0.3, notes: 'Extremely short; bedtime injection to sync with natural GH pulse' },
'PT-141': { halfLife: 2.5, notes: 'Melanocortin; onset ~1h, peak ~2–4h; intranasal or SC' },
'Epithalon': { halfLife: 0.5, notes: 'Telomerase activator; short half-life, course dosing protocol' },
'GHK-Cu': { halfLife: 1, notes: 'Copper peptide; topical or SC, frequent application' },
'GHK-CU': { halfLife: 1, notes: 'Copper peptide; topical or SC, frequent application' },
'Thymosin Alpha-1': { halfLife: 2, notes: 'Immune modulator; twice-weekly subcutaneous injection' },
'Selank': { halfLife: 0.1, notes: 'Very short intranasal half-life; effects last 4–6h centrally' },
'Semax': { halfLife: 0.1, notes: 'Very short intranasal; BDNF elevation persists hours after dose' },
'Retatrutide': { halfLife: 168, notes: 'GLP-1/GIP/Glucagon triagonist; once-weekly injection' },
'Semaglutide': { halfLife: 168, notes: 'GLP-1 agonist; once-weekly subcutaneous injection' },
'Tirzepatide': { halfLife: 120, notes: 'GLP-1/GIP dual agonist; once-weekly subcutaneous injection' },
'IGF-1 LR3': { halfLife: 20, notes: 'Long-acting IGF-1 analogue; daily or EOD injection' },
'MOTS-C': { halfLife: 0.5, notes: 'Mitochondrial peptide; short plasma half-life, daily injection' },
'SS-31': { halfLife: 1, notes: 'Mitochondria-targeting peptide; daily subcutaneous injection' },
'AOD-9604': { halfLife: 0.5, notes: 'HGH fragment; very short, divide into multiple daily doses' },
'Kisspeptin': { halfLife: 1, notes: 'HPG axis activator; short half-life, pulsatile dosing used' },
'Oxytocin': { halfLife: 0.08, notes: 'Extremely short plasma half-life (~5 min); intranasal preferred' },
'VIP': { halfLife: 1, notes: 'Short half-life; intranasal or IV/SC, multiple daily doses' },
'LL-37': { halfLife: 2, notes: 'Antimicrobial/immunomodulatory; SC injection or topical' },
'KPV': { halfLife: 0.5, notes: 'Anti-inflammatory tripeptide; oral or SC, multiple doses daily' },
'Pinealon': { halfLife: 1, notes: 'Pineal peptide; short half-life, short course protocols used' },
'PE-22-28': { halfLife: 1, notes: 'SPAK kinase inhibitor; short acting, intranasal or SC' },
'AICAR': { halfLife: 1, notes: 'AMPK activator; short half-life, daily subcutaneous injection' },
'SLU-PP-332': { halfLife: 2, notes: 'ERRα/γ agonist; oral or SC, daily dosing in research' },
'5-amino-1mq': { halfLife: 6, notes: 'NNMT inhibitor; oral bioavailability, once or twice daily' },
'DSIP': { halfLife: 0.5, notes: 'Delta sleep peptide; very short, typically IV or SC before sleep' },
'ARA-290': { halfLife: 2, notes: 'Tissue-protective EPO analogue; SC injection, no erythropoiesis' },
};
const PEPTIDE_LIBRARY = [
{
name: '5-amino-1mq',
aliases: ['5-amino-1-methylquinolinium', 'AMQ', 'NNMT inhibitor'],
description: 'A small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor that effectively raises intracellular NAD+ and SAM levels. Research shows fat mass reduction, improved insulin sensitivity, and metabolic benefits in animal models.',
halfLife: '~6 hours',
doseRange: '100–250 mg/day oral or 50–100 mg subcutaneous',
route: 'Oral or Subcutaneous',
mechanism: 'Inhibits NNMT, preventing degradation of NAD+ precursors. Raises NAD+, SAM, and methionine levels. Activates thermogenesis in white adipose tissue and improves mitochondrial function.',
protocols: 'Oral: 100–250 mg daily with food. SC: 50–100 mg/day. Cycles of 8–12 weeks are common in research. Effects on body composition take 4–6 weeks.',
cycleLength: '8–12 weeks',
stack: 'Synergistic with NAD+ precursors (NMN/NR). Often paired with other metabolic peptides like MOTS-C or AICAR for enhanced fat-loss effects.'
},
{
name: 'AICAR',
aliases: ['AICA ribonucleotide', '5-Aminoimidazole-4-carboxamide ribonucleoside', 'ZMP precursor'],
description: 'A naturally occurring intermediate in purine biosynthesis that potently activates AMPK (AMP-activated protein kinase). Known as the "exercise mimetic" for its ability to improve endurance, fat oxidation, and insulin sensitivity without exercise.',
halfLife: '~1 hour',
doseRange: '10–20 mg/kg research doses; practical: 50–200 mg/day SC',
route: 'Subcutaneous or Intravenous',
mechanism: 'Converts intracellularly to ZMP, a potent AMPK activator. Increases GLUT4 expression, fatty acid oxidation, and mitochondrial biogenesis via PGC-1α. Mimics the cellular energy response of exercise.',
protocols: 'Research protocols: 10–20 mg/kg SC daily for 1–4 weeks. Lower human-equivalent doses used in practice. Cycle 4–8 weeks; may be used pre-cardio.',
cycleLength: '4–8 weeks',
stack: 'Often combined with GW-501516 (cardarine) in research settings. Can be stacked with MOTS-C or SLU-PP-332 for additive metabolic effects.'
},
{
name: 'AOD-9604',
aliases: ['Anti-Obesity Drug 9604', 'HGH Fragment 177-191'],
description: 'A modified fragment of the C-terminus of human growth hormone (HGH) corresponding to amino acids 177–191. Developed as an anti-obesity drug, it retains the lipolytic properties of HGH without the anabolic or blood glucose effects.',
halfLife: '~30 minutes',
doseRange: '300–500 mcg/day',
route: 'Subcutaneous or Oral',
mechanism: 'Mimics the lipolytic domain of HGH. Stimulates fat breakdown (lipolysis) and inhibits lipogenesis specifically in adipose tissue. Does not bind to IGF-1 receptors so no anabolic or insulin resistance effects.',
protocols: 'Inject 300–500 mcg subcutaneously in the morning, fasted. Some protocols split into 2 doses. Oral forms show lower bioavailability but are used. Cycle 4–12 weeks.',
cycleLength: '4–12 weeks',
stack: 'Often stacked with CJC-1295/Ipamorelin for simultaneous fat loss and muscle preservation. Pairs with Sermorelin as a GHRH + fat-loss combination.'
},
{
name: 'ARA-290',
aliases: ['Cibinetide', 'ARA290', 'Helix B peptide'],
description: 'A non-hematopoietic EPO analogue engineered to provide the tissue-protective effects of erythropoietin (EPO) without stimulating red blood cell production. Studied for neuropathic pain, sarcoidosis, and diabetic complications.',
halfLife: '~2 hours',
doseRange: '4 mg SC 3× per week (clinical studies)',
route: 'Subcutaneous',
mechanism: 'Binds to the innate repair receptor (IRR), a heterodimer of EPO receptor and CD131. Activates anti-inflammatory and neuroprotective pathways without erythropoietic effects. Reduces small fiber neuropathy.',
protocols: 'Clinical protocols: 4 mg SC three times weekly for 28 days. Emerging research suggests 4 mg 3×/week for 4–8 weeks for nerve pain management.',
cycleLength: '4–8 weeks',
stack: 'Used as a standalone neuroprotective/anti-inflammatory agent. May be combined with BPC-157 for nerve injury recovery.'
},
{
name: 'Adalank',
aliases: ['Selank amidate', 'NA-Selank', 'N-Acetyl Selank Amidate'],
description: 'The N-acetyl amidate form of Selank with improved bioavailability and longer duration of action. Provides similar anxiolytic, nootropic, and immunomodulatory effects to Selank with lower dosing requirements and extended nasal absorption.',
halfLife: '~0.5–2 hours (extended vs Selank)',
doseRange: '100–200 mcg intranasal per day',
route: 'Intranasal',
mechanism: 'Same as Selank — modulates GABA-A receptor activity, increases BDNF, regulates serotonin and dopamine. The amidate modification reduces enzymatic degradation in nasal mucosa.',
protocols: 'Intranasal: 100–200 mcg per day in 1–2 divided doses. Cycle 2–4 weeks on with 1–2 weeks rest. Effects similar to Selank but more potent per dose.',
cycleLength: '2–4 weeks on / 1–2 weeks off',
stack: 'Often alternated or stacked with Semax/Adamax for comprehensive cognitive and anxiolytic effects.'
},
{
name: 'Adamax',
aliases: ['Semax amidate', 'NA-Semax', 'N-Acetyl Semax Amidate'],
description: 'The N-acetyl amidate modification of Semax, providing enhanced stability and longer action compared to regular Semax. Considered more potent on a mcg-for-mcg basis with stronger neuroprotective and cognitive-enhancing effects.',
halfLife: '~0.5–2 hours (extended vs Semax)',
doseRange: '100–300 mcg intranasal per day',
route: 'Intranasal',
mechanism: 'Enhanced version of Semax — stronger BDNF/NGF upregulation, increased neuroprotection, and more sustained dopaminergic/serotonergic modulation due to resistance to enzymatic breakdown.',
protocols: 'Intranasal: 100–300 mcg per day. Some use 50–100 mcg 2–3× daily. The amidated form requires lower doses than standard Semax. Cycle 2–4 weeks.',
cycleLength: '2–4 weeks on / 1–2 weeks off',
stack: 'Pairs well with Adalank (NA-Selank) for balanced stimulatory cognitive effects with anxiolytic support. Effective with NAD+ for neuroprotection.'
},
{
name: 'BPC-157',
aliases: ['Body Protection Compound 157', 'PL-10'],
description: 'A pentadecapeptide derived from a protective protein in human gastric juice. One of the most extensively studied healing peptides in animal research, showing remarkable regenerative effects on tendons, ligaments, muscles, gut, and neurological tissue.',
halfLife: '~4 hours',
doseRange: '250–500 mcg/day (5–10 mcg/kg)',
route: 'Subcutaneous, Intramuscular, or Oral (for GI use)',
mechanism: 'Upregulates growth hormone receptor expression, promotes angiogenesis via VEGFR2, activates the FAK-paxillin pathway critical for tendon cell healing, modulates nitric oxide production, and accelerates collagen synthesis.',
protocols: 'For injury: 250 mcg twice daily SC near injury site. For GI healing: 250–500 mcg orally twice daily in water. Typical cycle 4–8 weeks.',
cycleLength: '4–8 weeks',
stack: 'Gold standard stack: BPC-157 + TB-500 for soft tissue repair. Also pairs with GHK-Cu for wound healing and skin regeneration.'
},
{
name: 'Cerebrolysin',
aliases: ['FPF 1070', 'Cere'],
description: 'A mixture of neuropeptides and amino acids derived from pig brain proteins. Widely used in Eastern Europe and Asia for traumatic brain injury, stroke, Alzheimer\'s, and cognitive decline. One of the most clinically studied neuroprotective agents.',
halfLife: 'Rapid distribution; effects sustained 12–24h',
doseRange: '5–10 mL IV or IM, 5 days/week for 10–20 days',
route: 'Intravenous (preferred) or Intramuscular',
mechanism: 'Contains BDNF, NGF, CNTF, and other neurotrophic factors. Promotes neuroplasticity, reduces apoptosis, enhances cholinergic transmission, and protects against excitotoxicity.',
protocols: 'Standard course: 5–10 mL IV daily for 10–20 days. May be repeated 1–2× per year. IM use at 2–5 mL is less effective but more practical. Some use 1–2 mL SC off-label.',
cycleLength: '10–20 day course, repeat 1–2× per year',
stack: 'Used with Semax or Dihexa for synergistic neuroprotection. Combines well with NAD+ for comprehensive brain health protocols.'
},
{
name: 'CJC-1295',
aliases: ['CJC-1295 with DAC', 'CJC-1295 no-DAC', 'Mod GRF 1-29', 'Modified GRF'],
description: 'A GHRH (growth hormone releasing hormone) analogue that stimulates GH and IGF-1 release. The DAC version uses drug affinity complex technology for a dramatically extended half-life; the no-DAC version (Mod GRF 1-29) mimics natural pulsatile GHRH.',
halfLife: '168 hours (with DAC) / ~0.5 hours (no-DAC)',
doseRange: '1–2 mg/week (DAC) or 100–200 mcg/injection (no-DAC)',
route: 'Subcutaneous',
mechanism: 'Binds and activates GHRH receptors in the anterior pituitary, stimulating GH release and downstream IGF-1 production from the liver. DAC version maintains continuous GH elevation.',
protocols: 'CJC-1295 with DAC: 1–2 mg SC once weekly. No-DAC: 100–200 mcg 2–3× daily with a GHRP. Both forms work best when administered fasted.',
cycleLength: '3–6 months',
stack: 'No-DAC pairs with Ipamorelin for clean GH pulses. DAC version alone or with Ipamorelin for sustained elevation. Popular GH stack: CJC-1295 no-DAC + Ipamorelin 2–3× daily.'
},
{
name: 'CJC-195/IPA',
aliases: ['CJC/Ipamorelin combo', 'CJC-Ipa blend', 'Ipamorelin/CJC-1295'],
description: 'A pre-mixed combination of CJC-1295 (no-DAC, Mod GRF 1-29) and Ipamorelin. Represents the most popular GH peptide stack in the research community — the GHRH + GHRP combination that produces synergistically amplified GH pulses.',
halfLife: 'CJC component ~0.5h, Ipamorelin ~2h',
doseRange: '200–300 mcg of combination per injection, 2–3× daily',
route: 'Subcutaneous',
mechanism: 'CJC-1295 component amplifies the pituitary response; Ipamorelin triggers the GH pulse via ghrelin receptor. Together they produce a 2–10× larger GH pulse than either alone.',
protocols: 'Inject 200–300 mcg 2–3× daily: upon waking, pre-workout, and before sleep. Administer fasted (2h food restriction before and 30 min after). Cycle 3–6 months.',
cycleLength: '3–6 months',
stack: 'This IS the primary GH stack. Can layer with AOD-9604 for fat loss or BPC-157/TB-500 for recovery. Add peptides to the stack individually for specific goals.'
},
{
name: 'DSIP',
aliases: ['Delta Sleep-Inducing Peptide'],
description: 'A naturally occurring neuropeptide discovered in rabbit blood that induces delta (slow-wave) sleep. Also studied for stress reduction, normalization of circadian rhythms, and modulation of hypothalamic-pituitary function.',
halfLife: '~30 minutes',
doseRange: '100–300 mcg per dose before sleep',
route: 'Intravenous, Subcutaneous, or Intranasal',
mechanism: 'Acts on delta wave sleep generators in the brain. Modulates ACTH, LH, and somatostatin release. May reduce cortisol and normalize disturbed sleep architecture. Exact CNS receptor not fully characterized.',
protocols: 'Inject 100–300 mcg SC or IV 30–60 minutes before intended sleep. Best used as a 5–10 day course for sleep normalization rather than nightly. Intranasal at 200–400 mcg also used.',
cycleLength: '5–10 day course as needed',
stack: 'Stacked with Epithalon for circadian rhythm and sleep optimization. Some pair with BPC-157 for overall recovery protocols.'
},
{
name: 'Dihexa',
aliases: ['PNB-0408', 'N-hexanoic-Tyr-Ile-(6) aminohexanoic amide'],
description: 'An ultra-potent nootropic peptide and HGF/MET agonist. Research suggests it is approximately 1,000,000× more potent than BDNF at facilitating hippocampal synaptic connectivity. Originally developed for Alzheimer\'s research.',
halfLife: '~2–4 hours (estimated)',
doseRange: '1–10 mg per dose (oral); 1–3 mg SC. Active at mcg range in some studies.',
route: 'Oral or Subcutaneous',
mechanism: 'Acts as an HGF/c-MET receptor agonist, dramatically enhancing synaptogenesis (new synapse formation) in the hippocampus. Increases dendrite density and cognitive function in animal models of neurodegeneration.',
protocols: 'Start very low: 1–2 mg oral or 1 mg SC. Some users report cognitive effects at mcg doses. Use 2–3× per week due to long functional duration. Cycle 4–8 weeks.',
cycleLength: '4–8 weeks with breaks',
stack: 'Used alongside Cerebrolysin or Semax for additive neuroprotective and cognitive enhancement. NAD+ is a natural complement.'
},
{
name: 'Epithalon',
aliases: ['Epitalon', 'Epithalamin', 'Ala-Glu-Asp-Gly'],
description: 'A synthetic tetrapeptide derived from Epithalamin, a natural extract of the pineal gland. Extensively researched by the V.N. Khavinson group at the St. Petersburg Institute of Bioregulation for over 30 years. Studied for telomere elongation, longevity, and circadian normalization.',
halfLife: '~30 minutes',
doseRange: '5–10 mg/day for 10–20 consecutive days',
route: 'Subcutaneous or Intravenous',
mechanism: 'Activates telomerase enzyme to lengthen telomeres in somatic cells. Regulates melatonin production by normalizing pineal gland function. Modulates cortisol rhythm and demonstrates antioxidant effects in aging tissues.',
protocols: '10-day course: 5–10 mg SC daily for 10 consecutive days. Repeat 1–2× per year. Some prefer 20-day courses at 3 mg 3× daily. IV use preferred for maximum bioavailability.',
cycleLength: '10–20 day course, 1–2× per year',
stack: 'Anti-aging stack: Epithalon + Pinealon + GHK-Cu. Thymosin Alpha-1 is a common companion for immune system support.'
},
{
name: 'GHK-CU',
aliases: ['GHK-Cu', 'Copper peptide', 'Glycyl-L-histidyl-L-lysine copper'],
description: 'A tripeptide-copper complex naturally found in human plasma, saliva, and urine. Levels decline significantly with age. Among the most studied peptides for wound healing, anti-aging skin effects, hair growth stimulation, and systemic antioxidant activity.',
halfLife: '~1 hour',
doseRange: '1–2 mg/day subcutaneous; topical concentration varies (0.1–3%)',
route: 'Subcutaneous, Topical, or Intranasal',
mechanism: 'Activates over 4,000 genes related to wound healing, collagen/elastin synthesis, and anti-aging. Recruits stem cells to injury sites, upregulates antioxidant enzymes (SOD, catalase), and modulates TGF-β signaling.',
protocols: 'Injectable: 1–2 mg SC daily for 4–6 weeks. Topical: apply 1–2× daily to target areas. For hair: scalp application 2× daily. Cycle injectable use; topical can be continuous.',
cycleLength: '4–6 weeks injectable; topical ongoing',
stack: 'Core of the "Glow" and "Klow" blends with BPC-157 and TB-500. Excellent topical pairing with tretinoin, vitamin C. For systemic anti-aging: stack with Epithalon and Thymosin Alpha-1.'
},
{
name: 'GhRIP',
aliases: ['GHRP blend', 'GH Releasing Combo'],
description: 'A combination blend of GHRP peptides (typically GHRP-6 and/or GHRP-2 with Ipamorelin). Designed to provide comprehensive growth hormone releasing peptide coverage through multiple receptor activation pathways.',
halfLife: '1–2 hours',
doseRange: '100–300 mcg per injection, 2–3× daily',
route: 'Subcutaneous',
mechanism: 'Combines multiple GHRP receptor agonists for amplified GH release. GHRP-6 and GHRP-2 have appetite-stimulating properties; Ipamorelin component provides clean GH release without significant cortisol elevation.',
protocols: 'Inject 100–300 mcg 2–3× daily, fasted. Best used with a GHRH like CJC-1295 for synergistic GH amplification.',
cycleLength: '3–6 months',
stack: 'Used as the GHRP component with any GHRH (CJC-1295, Sermorelin, Tesamorelin). Core of many GH optimization protocols.'
},
{
name: 'Glow',
aliases: ['BBG70', 'BPC+TB+GHK blend', 'Wolverine Plus'],
description: 'A proprietary blend combining BPC-157 (10 mg), TB-500 (10 mg), and GHK-Cu (50 mg) per vial. Offers the combined healing properties of all three peptides in a single injection — soft tissue repair, systemic healing, and regenerative copper peptide benefits.',
halfLife: 'Varies by component (BPC: 4h, TB-500: 24h, GHK-Cu: 1h)',
doseRange: '1 vial (70 mg blend) once or twice weekly',
route: 'Subcutaneous',
mechanism: 'Combines BPC-157\'s targeted tendon/gut healing, TB-500\'s systemic cell migration and anti-inflammation, and GHK-Cu\'s collagen synthesis and antioxidant gene activation.',
protocols: 'Typically 1 vial per week for maintenance, or 2× weekly during active injury recovery. Can be used as a standalone comprehensive healing protocol.',
cycleLength: '4–8 weeks',
stack: 'Already a triple-stack. Can add Thymosin Alpha-1 for immune support or Sermorelin/Ipamorelin for GH optimization alongside.'
},
{
name: 'Glutathione',
aliases: ['GSH', 'gamma-Glutamylcysteinylglycine', 'Reduced Glutathione'],
description: 'The body\'s master antioxidant and detoxification molecule. A tripeptide naturally produced in every cell. Injectable glutathione provides direct systemic antioxidant support, liver protection, skin brightening, and immune enhancement beyond what oral supplementation achieves.',
halfLife: 'Rapid distribution; tissue levels sustained hours',
doseRange: '600–1200 mg IV or IM push, 2–5× per week',
route: 'Intravenous, Intramuscular, or Nebulized',
mechanism: 'Directly neutralizes reactive oxygen species (ROS) and free radicals. Cofactor for glutathione peroxidase, regenerates vitamins C and E. Supports Phase II liver detoxification, reduces melanin synthesis, and modulates NK cell activity.',
protocols: 'IV push: 600–1200 mg in normal saline over 2–10 minutes, 2–5× per week. IM: 600 mg 2–3× per week. Nebulized: 100–200 mg for respiratory indications.',
cycleLength: 'Ongoing or 4–8 week courses',
stack: 'Synergistic with vitamin C IV (given separately to avoid precipitation). Pairs with NAD+ for comprehensive cellular health. Used in detox protocols with alpha-lipoic acid.'
},
{
name: 'IGF-1 LR3',
aliases: ['Long R3 IGF-1', 'Insulin-like Growth Factor-1 Long Arg3'],
description: 'A modified form of insulin-like growth factor-1 with an extended amino acid sequence that significantly reduces binding to IGF-binding proteins, resulting in a greatly extended half-life and enhanced biological activity compared to endogenous IGF-1.',
halfLife: '~20–30 hours',
doseRange: '20–120 mcg/day (research context)',
route: 'Subcutaneous or Intramuscular',
mechanism: 'Binds IGF-1 receptors to promote muscle cell hyperplasia (new cell creation), protein synthesis, glucose uptake, and fat oxidation. The LR3 modification reduces IGFBP binding, keeping it freely active in circulation.',
protocols: 'Research protocols: 20–60 mcg SC or IM once daily or split into pre/post workout doses. Typical research cycles are 4–6 weeks due to receptor downregulation. Highly glucose-lowering — take with food.',
cycleLength: '4–6 weeks with breaks to prevent receptor desensitization',
stack: 'Often used after GH peptide cycles. Synergistic with CJC-1295/Ipamorelin stack. Pairs with BPC-157/TB-500 for injury recovery with simultaneous muscle preservation.'
},
{
name: 'Ipamorelin',
aliases: ['Ipam', 'NNC 26-0161'],
description: 'A pentapeptide GHRP (growth hormone releasing peptide) considered the most selective GH secretagogue available. Stimulates robust GH release with the cleanest safety profile of all GHRPs — minimal effect on cortisol, prolactin, or appetite.',
halfLife: '~2 hours',
doseRange: '200–300 mcg per injection, 2–3× daily',
route: 'Subcutaneous',
mechanism: 'Selectively binds ghrelin/GHSR receptors in the pituitary, triggering GH release without meaningfully elevating cortisol or prolactin. The selective nature makes it ideal for long-term use.',
protocols: 'Inject 200–300 mcg SC 2–3× daily: morning fasted, pre-workout (fasted), and before bed. No food 2h before or 30 min after injection for maximum GH pulse.',
cycleLength: '3–6 months; can be used long-term',
stack: 'The standard GH optimization stack: CJC-1295 no-DAC + Ipamorelin 2–3× daily. Add Sermorelin or Tesamorelin as the GHRH component for variety.'
},
{
name: 'KPV',
aliases: ['Lys-Pro-Val', 'LYSINE-PROLINE-VALINE', 'Alpha-MSH tripeptide C-terminal'],
description: 'A tripeptide derived from the C-terminus of alpha-MSH (alpha-melanocyte-stimulating hormone). Potent anti-inflammatory effects, particularly in the gut. Shows promise for IBD, Crohn\'s disease, skin inflammation, and general inflammatory conditions.',
halfLife: '~30 minutes (oral rapidly metabolized)',
doseRange: '100–500 mcg SC/day; oral doses 500 mcg–5 mg (lower bioavailability)',
route: 'Subcutaneous or Oral',
mechanism: 'Inhibits NF-κB signaling pathway, reducing production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β). Particularly effective in gut epithelial cells and melanocytes. Activates MC1R to suppress inflammation.',
protocols: 'GI inflammation: oral 500 mcg–2 mg with meals. Systemic: 100–300 mcg SC daily. Common in the "Klow" blend. Short cycles of 4–8 weeks or as needed.',
cycleLength: '4–8 weeks or as needed',
stack: 'Core component of "Klow" blend (BPC-157 + TB-500 + GHK-Cu + KPV). Excellent pairing with BPC-157 for comprehensive gut healing.'
},
{
name: 'Kisspeptin',
aliases: ['Kisspeptin-10', 'KP-10', 'Metastin fragment'],
description: 'A neuropeptide encoded by the KISS1 gene that plays a critical role in initiating puberty and regulating the hypothalamic-pituitary-gonadal (HPG) axis. Used to stimulate LH/FSH release and restore natural testosterone production.',
halfLife: '~1–2 hours',
doseRange: '9.6–68 mcg/kg as research bolus; practical: 50–100 mcg SC',
route: 'Subcutaneous or Intranasal',
mechanism: 'Binds kisspeptin-1 receptor (KISS1R/GPR54) in the hypothalamus, stimulating GnRH release, which in turn triggers LH and FSH secretion from the pituitary, ultimately increasing testosterone and restoring HPG axis function.',
protocols: 'Post-cycle or TRT support: 50–100 mcg SC, 2–3× daily for 2–4 weeks. Some use intranasal formulations. Best used alongside hCG or Sermorelin for comprehensive hormonal restoration.',
cycleLength: '2–4 weeks (PCT) or ongoing for HPG axis support',
stack: 'HPG axis restoration stack: Kisspeptin + hCG + Gonadorelin. May pair with Epithalon for hormonal rhythm normalization.'
},
{
name: 'Klow',
aliases: ['BBKG80', 'KLOW80', 'BPC+TB+GHK+KPV blend'],
description: 'An expanded proprietary blend combining BPC-157 (10 mg), TB-500 (10 mg), GHK-Cu (50 mg), and KPV (10 mg) per vial. The "Klow" adds KPV\'s anti-inflammatory tripeptide to the "Glow" blend for enhanced gut protection and systemic anti-inflammatory coverage.',
halfLife: 'Varies by component (BPC-157: 4h, TB-500: 24h, GHK-Cu: 1h, KPV: 0.5h)',
doseRange: '1 vial (80 mg total) once or twice weekly',
route: 'Subcutaneous',
mechanism: 'Combines four synergistic peptides: BPC-157 (tendon/gut healing, angiogenesis), TB-500 (systemic healing, anti-inflammation), GHK-Cu (collagen synthesis, antioxidant gene activation), and KPV (NF-κB inhibition, cytokine suppression).',
protocols: 'One vial per week for general recovery; up to 2× weekly during active injury/inflammatory phase. Suitable as a comprehensive healing protocol for those wanting all-in-one convenience.',
cycleLength: '4–8 weeks, can extend for maintenance',
stack: 'Already a comprehensive 4-component stack. Can add Thymosin Alpha-1 for immune modulation or GH peptides (CJC-1295/Ipamorelin) for complete recovery and optimization.'
},
{
name: 'LL-37',
aliases: ['Cathelicidin', 'hCAP-18/LL-37', 'Antimicrobial peptide LL-37'],
description: 'The only human cathelicidin antimicrobial peptide, naturally produced in neutrophils, macrophages, and epithelial cells. Provides broad-spectrum antimicrobial activity while also modulating wound healing, immune responses, and potentially tumor suppression.',
halfLife: '~2 hours',
doseRange: '100–500 mcg/day subcutaneous in research protocols',
route: 'Subcutaneous or Topical',
mechanism: 'Disrupts bacterial cell membranes (broad-spectrum antimicrobial). Binds formyl peptide receptor-like 1 (FPRL1) to modulate innate immunity. Stimulates angiogenesis, keratinocyte migration, and wound healing. May have antiviral and antifungal properties.',
protocols: 'Research: 100–300 mcg SC daily for 2–4 weeks. Topical preparations used for skin infections. Chronic low-dose use studied for lupus, rosacea, and chronic infections.',
cycleLength: '2–4 weeks',
stack: 'Anti-infective/healing stack: LL-37 + BPC-157. For skin conditions: LL-37 + GHK-Cu topically. Thymosin Alpha-1 complement for immune support.'
},
{
name: 'Lipo-C',
aliases: ['LIPO-C', 'MIC+B vitamins injection', 'Lipotropic injection'],
description: 'A proprietary lipotropic injection formula containing amino acids (methionine, inositol, choline), L-carnitine, and B vitamins (B5, B6, B12). Used to support fat metabolism, liver function, energy production, and weight management.',
halfLife: 'Varies by component; B12 stored in liver',
doseRange: '1 mL SC or IM, 1–3× per week',
route: 'Subcutaneous or Intramuscular',
mechanism: 'Methionine: methyl donor for fat metabolism. Inositol: lipotropic, reduces liver fat, improves insulin signaling. Choline: phospholipid synthesis, liver fat mobilization. L-carnitine: transports fatty acids into mitochondria. B vitamins: energy cofactors.',
protocols: '1 mL SC or IM injection, 1–3× per week. Often used alongside caloric deficit and exercise. B12 component provides energy boost within hours of injection.',
cycleLength: 'Ongoing or 8–12 week cycles',
stack: 'Fat loss support stack: Lipo-C + AOD-9604. Combine with Semaglutide or GLP-1 agonists for enhanced weight management. Good complement to any metabolic protocol.'
},
{
name: 'MOTS-C',
aliases: ['Mitochondrial ORF of the 12S rRNA type-c', 'Humanin analog'],
description: 'A mitochondria-derived peptide encoded within the 12S rRNA gene of mitochondrial DNA. Acts as an exercise-mimetic by activating AMPK pathways, improving insulin sensitivity, reducing fat accumulation, and increasing cellular stress resistance.',
halfLife: '~30 minutes in plasma',
doseRange: '5–15 mg/week SC or IM; research doses 0.5 mg/kg',
route: 'Subcutaneous or Intramuscular',
mechanism: 'Translocates from mitochondria to the nucleus under metabolic stress. Activates AMPK and AICAR signaling, improves glucose uptake, inhibits lipid accumulation, and increases mitochondrial biogenesis. Levels decline with age.',
protocols: '5 mg 1–3× per week SC. Some protocols use 10 mg 2× per week. Cycle 8–12 weeks. Often injected pre-exercise for enhanced metabolic effects.',
cycleLength: '8–12 weeks',
stack: 'Metabolic stack: MOTS-C + AICAR + 5-amino-1mq for comprehensive AMPK activation. Synergistic with SLU-PP-332 for exercise mimetic effects. NAD+ is a natural complement.'
},
{
name: 'NAD+',
aliases: ['Nicotinamide Adenine Dinucleotide', 'NAD', 'NAD+ IV'],
description: 'A coenzyme present in all living cells, critical for energy metabolism, DNA repair, sirtuin activation, and cellular signaling. Levels decline dramatically with age. Injectable NAD+ bypasses oral bioavailability issues to directly raise cellular NAD+ levels.',
halfLife: 'Rapid cellular uptake; IV preferred for maximum delivery',
doseRange: '500–1000 mg IV infusion; 100–500 mg SC daily',
route: 'Intravenous (preferred), Subcutaneous, or Intramuscular',
mechanism: 'Substrate for sirtuins (SIRT1–7) that regulate gene expression, metabolism, and stress resistance. Fuels cellular energy (ATP) production, activates PARP DNA repair enzymes, and modulates the immune system. Also converts to NADH which drives mitochondrial electron transport.',
protocols: 'IV: 500–1000 mg over 2–4 hours (slow push to avoid side effects: nausea, flushing). SC: 100–300 mg daily in the morning. Sublingual NMN/NR are oral precursors as lower-cost alternatives.',
cycleLength: 'Ongoing or quarterly 5–10 day IV courses',
stack: 'Anti-aging core: NAD+ + Epithalon + GHK-Cu. Metabolic stack: NAD+ + MOTS-C + 5-amino-1mq. Cognitive: NAD+ + Semax + Dihexa. The most fundamental longevity intervention.'
},
{
name: 'Oxytocin',
aliases: ['The bonding hormone', 'OT', 'Pitocin'],
description: 'A naturally occurring neuropeptide produced in the hypothalamus, released by the posterior pituitary. Known as the "love hormone" or "bonding hormone," it regulates social bonding, trust, empathy, sexual arousal, uterine contraction, and lactation.',
halfLife: '~5 minutes in blood (intranasal effects last 1–2 hours)',
doseRange: '8–40 IU intranasal; 0.5–2 mg SC',
route: 'Intranasal (most common), Subcutaneous, or Intravenous',
mechanism: 'Binds oxytocin receptors in the brain (limbic system, hypothalamus) to modulate social behavior, reduce cortisol/anxiety, and enhance trust and bonding. Peripherally: triggers uterine contraction, milk ejection, and modulates pain pathways.',
protocols: 'Intranasal: 8–40 IU (0.5–2.5 mL) 30–60 minutes before social activity or intimacy. SC: 0.5–2 mg as needed. Not typically used continuously — as-needed dosing preferred.',
cycleLength: 'As needed, not continuous',
stack: 'Often combined with PT-141 for enhanced sexual function and intimacy. Some pair with Selank for anxiety reduction + social enhancement.'
},
{
name: 'PE-22-28',
aliases: ['PE22-28', 'Spadin analog', 'TREK-1 blocker'],
description: 'A synthetic peptide derived from the neurotensin peptide sortilin binding domain. Functions as a TREK-1 potassium channel blocker with rapid antidepressant effects. Studies show depression reversal within hours — faster onset than SSRIs/SNRIs.',
halfLife: '~1–2 hours',
doseRange: '50–200 mcg intranasal or SC per day',
route: 'Intranasal or Subcutaneous',
mechanism: 'Blocks TREK-1 (TWIK-related K+ channel), which normally inhibits serotonergic neurons. Blocking TREK-1 increases serotonin release and signaling. Activates BDNF/TrkB pathways. Rapid onset distinguishes it from classical antidepressants.',
protocols: 'Intranasal: 100–200 mcg once or twice daily. SC: 50–100 mcg daily. Effects typically noticed within 1–7 days. Cycle 4–8 weeks; best used during acute depressive episodes.',
cycleLength: '4–8 weeks or as needed',
stack: 'Antidepressant stack: PE-22-28 + Semax + Selank for comprehensive mood and cognition support. Some pair with Cerebrolysin for neuroplasticity.'
},
{
name: 'PT-141',
aliases: ['Bremelanotide', 'Vyleesi'],
description: 'A melanocortin receptor agonist originally developed from the tanning peptide Melanotan II. FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Effective for both male and female sexual dysfunction through central (not vascular) mechanisms.',
halfLife: '~2.5 hours',
doseRange: '0.5–2 mg per dose as needed',
route: 'Subcutaneous or Intranasal',
mechanism: 'Activates melanocortin receptors MC3R and MC4R in the CNS (hypothalamus and limbic system), directly increasing sexual arousal and desire through neural pathways. Unlike PDE5 inhibitors, works regardless of vascular function.',
protocols: 'Inject 0.5–2 mg SC 1–2 hours before sexual activity. Start with 0.5–1 mg to assess tolerability (common side effects: nausea, flushing). Maximum once per 72 hours. Intranasal: 1.75 mg per spray.',
cycleLength: 'As-needed; not daily use',
stack: 'Often paired with Oxytocin for enhanced bonding and intimacy. Some combine with Cialis/Tadalafil for men. Not stacked with other melanocortins.'
},
{
name: 'Pinealon',
aliases: ['Ala-Glu-Asp tripeptide', 'AED', 'pineal peptide bioregulator'],
description: 'A tripeptide bioregulator (Glu-Asp-Arg in some sources, Ala-Glu-Asp in others) designed to target the pineal gland and central nervous system. Developed by the St. Petersburg group alongside Epithalon. Used for sleep disorders, neuroprotection, and neurological aging.',
halfLife: '~1 hour',
doseRange: '5–10 mg/day for 10 days',
route: 'Subcutaneous',
mechanism: 'Acts as a peptide bioregulator targeting nervous tissue gene expression. Shown to reduce age-related neurodegeneration, normalize melatonin synthesis, improve cognitive function, and protect against neurotoxicity in animal studies.',
protocols: '10-day course: 5–10 mg SC daily for 10 consecutive days. May repeat 1–2× per year. Often used alongside Epithalon in comprehensive anti-aging pineal gland protocols.',
cycleLength: '10-day course, 1–2× per year',
stack: 'Anti-aging nervous system stack: Pinealon + Epithalon. Add Cerebrolysin for stronger neuroprotective effects. Thymosin Alpha-1 provides complementary immune support.'
},
{
name: 'Retatrutide',
aliases: ['LY3437943', 'GLP-1/GIP/Glucagon triple agonist', 'Triagonist'],
description: 'A single molecule triple agonist targeting GLP-1, GIP, and glucagon receptors. In Phase 2 trials showed up to 24% body weight reduction over 48 weeks — more than any previously approved weight loss drug. Among the most powerful GLP-1 class agents studied.',
halfLife: '~7 days (once-weekly dosing)',
doseRange: '1–12 mg/week SC (gradual escalation)',
route: 'Subcutaneous',
mechanism: 'GLP-1 receptor: reduces appetite, slows gastric emptying, improves insulin secretion. GIP receptor: enhances insulin sensitivity and fat utilization. Glucagon receptor: increases energy expenditure and hepatic glucose output. Triple mechanism provides superior weight loss vs dual agonists.',
protocols: 'Gradual dose escalation over 12–24 weeks: start 1–2 mg/week, increase by 2 mg every 4 weeks to 8–12 mg/week. Maintain for 24–48 weeks. Taper before discontinuing to minimize rebound.',
cycleLength: '24–52 weeks (long-term protocol)',
stack: 'Weight loss stack: Retatrutide + AOD-9604 or Lipo-C for enhanced fat metabolism. Add resistance training protocol for body composition optimization. Avoid stacking with other GLP-1 agents.'
},
{
name: 'SS-31',
aliases: ['Elamipretide', 'MTP-131', 'Bendavia', 'D-Arg-2\'6\'-Dmt-Lys-Phe-NH2'],
description: 'A mitochondria-targeting tetrapeptide that selectively accumulates in the inner mitochondrial membrane. Shown to protect and restore mitochondrial function in aging and disease. Studied for heart failure, kidney disease, muscular dystrophy, and age-related decline.',
halfLife: '~1–2 hours in plasma; concentrates in mitochondria',
doseRange: '0.1–0.5 mg/kg SC daily; practical: 10–50 mg/day',
route: 'Subcutaneous or Intravenous',
mechanism: 'Binds cardiolipin in the inner mitochondrial membrane, restoring cristae architecture and electron transport chain efficiency. Reduces mitochondrial ROS production, prevents cytochrome c release (apoptosis), and restores ATP synthesis in aging/stressed cells.',
protocols: 'Daily SC injection: 10–50 mg/day. Some research uses 5-day-on / 2-day-off cycles. IV infusion at clinical doses 0.05–0.25 mg/kg. Cycle 4–8 weeks.',
cycleLength: '4–8 weeks with breaks',
stack: 'Mitochondrial health stack: SS-31 + MOTS-C + NAD+ for comprehensive mitochondrial support. Synergistic with Epithalon for anti-aging. Pairs with ARA-290 for neuroprotection.'
},
{
name: 'SLU-PP-332',
aliases: ['SLU PP-332', 'ERRα/γ agonist', 'Nuclear receptor agonist'],
description: 'A potent synthetic agonist of estrogen-related receptors α and γ (ERRα/ERRγ), which are master regulators of mitochondrial biogenesis and oxidative metabolism. Research shows it mimics endurance exercise at the molecular level, increasing running capacity by 70% in mice.',
halfLife: '~2 hours',
doseRange: '10–30 mg/kg research doses; practical: 50–200 mg SC or oral',
route: 'Subcutaneous or Oral',
mechanism: 'Activates ERRα and ERRγ transcription factors, which drive PGC-1α coactivation and mitochondrial biogenesis. Increases oxidative muscle fiber expression, fatty acid oxidation capacity, and endurance without physical exercise.',
protocols: 'Oral: 100–200 mg/day. SC: 50–100 mg/day. Pre-cardio dosing suggested. Cycle 4–8 weeks. Very early in human research — exercise caution with dosing.',
cycleLength: '4–8 weeks',
stack: 'Exercise mimetic stack: SLU-PP-332 + AICAR + MOTS-C. Each activates different aspects of exercise adaptation. Can layer with GLP-1 agonists for body recomposition.'
},
{
name: 'Semax',
aliases: ['ACTH 4-10 Pro-Gly-Pro', 'N-Acetyl Semax', 'Mexidol analog'],
description: 'A synthetic heptapeptide derived from ACTH (4–10) with an additional Pro-Gly-Pro sequence. Approved pharmaceutical in Russia and Ukraine. Widely used for stroke recovery, cognitive enhancement, ADHD, anxiety, and neuroprotection.',
halfLife: 'Minutes in blood (intranasal); cognitive effects persist 4–8 hours',
doseRange: '200–900 mcg/day intranasal; 50–300 mcg SC',
route: 'Intranasal (preferred) or Subcutaneous',
mechanism: 'Rapidly increases BDNF and NGF in hippocampus and cortex. Modulates dopamine and serotonin receptor activity. Enhances cholinergic transmission. Has direct antioxidant and anti-inflammatory effects in the CNS. Also shown to increase HIF-1α (hypoxia inducible factor).',
protocols: 'Intranasal: 200–600 mcg per day in 2–3 divided doses (1–2 drops per nostril = ~25 mcg per drop at 0.1% solution). SC: 50–200 mcg once daily. Cycle 2–4 weeks, rest 1–2 weeks.',
cycleLength: '2–4 weeks on / 1–2 weeks off',
stack: 'Classic cognitive stack: Semax + Selank (stimulating cognition + anxiolytic). Add Cerebrolysin for stroke/TBI recovery. PE-22-28 for combined depression and cognition support.'
},
{
name: 'Selank',
aliases: ['TP-7', 'Tuftsin analog', 'Anxiolytic peptide'],
description: 'A synthetic heptapeptide analogue of the immunomodulatory tetrapeptide Tuftsin. Approved anxiolytic and nootropic drug in Russia. Provides anxiolytic effects comparable to benzodiazepines without sedation, tolerance, or dependence.',
halfLife: 'Minutes in plasma; central effects last 4–6 hours',
doseRange: '250–1000 mcg/day intranasal',
route: 'Intranasal (preferred) or Subcutaneous',
mechanism: 'Modulates GABA-A receptor function (anxiolytic mechanism). Increases BDNF and serotonin signaling. Upregulates IL-2 and interferon-γ (immune modulation). Normalizes enkephalin metabolism, providing anti-anxiety effects without receptor downregulation.',
protocols: 'Intranasal: 250–500 mcg twice daily, or 1000 mcg as a single dose. Can be used acutely before stressful events. Cycle 2–4 weeks or use as-needed. SC: 250–500 mcg daily.',
cycleLength: '2–4 weeks or as-needed use',
stack: 'The quintessential cognitive/anxiety stack: Semax + Selank. Pairs with PE-22-28 for depression. Useful alongside Oxytocin for social anxiety scenarios.'
},
{
name: 'Semaglutide',
aliases: ['Ozempic', 'Wegovy', 'Rybelsus', 'GLP-1 agonist'],
description: 'A long-acting GLP-1 receptor agonist originally developed for type 2 diabetes but now widely used for obesity management (Wegovy). Demonstrated 15–18% average body weight loss in clinical trials. One of the most widely prescribed medications globally.',
halfLife: '~7 days (once-weekly dosing)',
doseRange: '0.25–2.4 mg/week SC (escalation over 16–20 weeks)',
route: 'Subcutaneous (weekly) or Oral (daily, lower efficacy)',
mechanism: 'Activates GLP-1 receptors in the pancreas (stimulates insulin, suppresses glucagon), hypothalamus (reduces appetite/hunger signals), and GI tract (slows gastric emptying). Also reduces cardiovascular inflammation and improves lipid profiles.',
protocols: 'Dose escalation: 0.25 mg/week × 4 weeks → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg. Each step lasts 4 weeks. Max dose 2.4 mg/week for weight loss (Wegovy) or 2 mg for diabetes (Ozempic).',
cycleLength: 'Long-term; gradual taper if discontinuing to minimize rebound',
stack: 'Weight loss: Semaglutide + AOD-9604 + Lipo-C. Add resistance training for body recomposition. Metformin sometimes added for enhanced insulin sensitization. Not stacked with other GLP-1 agents.'
},
{
name: 'Sermorelin',
aliases: ['GHRH 1-29', 'Geref'],
description: 'The first 29 amino acids of endogenous growth hormone releasing hormone (GHRH). The shortest fragment of GHRH that retains full biological activity. FDA-approved for GH deficiency in children; widely used off-label in adults for GH optimization and anti-aging.',
halfLife: '~11–12 minutes (very short)',
doseRange: '200–500 mcg before bed',
route: 'Subcutaneous',
mechanism: 'Binds GHRH receptors in the anterior pituitary, stimulating the synthesis and secretion of GH. Also increases IGF-1 production. Unlike synthetic GH, Sermorelin maintains the natural feedback loop — pituitary remains responsive to somatostatin.',
protocols: 'Inject 200–500 mcg SC at bedtime (synchronizes with natural nocturnal GH pulse). Some practitioners use 200 mcg 2× daily (morning + bedtime). Cycle ongoing with breaks every 3–6 months.',
cycleLength: '3–6 months',
stack: 'Often combined with Ipamorelin or GHRP-6 for enhanced GH release. The Sermorelin + Ipamorelin combination is a clean, effective GH stack. Add BPC-157/TB-500 for healing.'
},
{
name: 'TB-500',
aliases: ['Thymosin Beta-4', 'Tβ4'],
description: 'A synthetic version of Thymosin Beta-4, a naturally occurring 43-amino acid protein present in virtually every cell of the body. Provides systemic healing effects — particularly relevant for cardiovascular tissue, muscles, tendons, skin, and neurological injury. Has a broad systemic reach vs BPC-157\'s more localized action.',
halfLife: '~24 hours',
doseRange: '2–2.5 mg 2× per week (loading); 2.5 mg once weekly (maintenance)',
route: 'Subcutaneous or Intramuscular',
mechanism: 'Sequesters actin monomers, modulating cytoskeletal dynamics and promoting cell migration. Stimulates angiogenesis via VEGF. Reduces inflammatory cytokines (TNF-α, IL-1β). Activates stem cell mobilization from bone marrow.',
protocols: 'Loading phase: 2–2.5 mg 2× per week for 4–6 weeks. Maintenance: 2.5 mg once weekly or bi-weekly. For cardiac applications, some protocols use higher doses under medical supervision.',
cycleLength: '4–6 weeks loading, then maintenance',
stack: 'The gold standard injury recovery stack: TB-500 + BPC-157. Together they cover both systemic (TB-500) and local (BPC-157) healing mechanisms comprehensively.'
},
{
name: 'Tesamorelin',
aliases: ['Egrifta', 'TH9507', 'GHRH analogue'],
description: 'A stabilized analogue of GHRH (growth hormone releasing hormone) with a trans-3-hexenoic acid modification for improved stability. FDA-approved for HIV-associated lipodystrophy (excess abdominal fat). Studied for cognitive protection in older adults and general body composition improvement.',
halfLife: '~26 minutes (very short acting)',
doseRange: '1–2 mg/day SC',
route: 'Subcutaneous',
mechanism: 'Binds GHRH receptors in the pituitary, stimulating GH and IGF-1 release. The chemical modification provides superior stability compared to native GHRH while retaining receptor specificity. GH stimulation reduces visceral fat and preserves the natural pulsatile GH rhythm.',
protocols: 'Inject 1–2 mg SC once daily in the morning or evening. Clinical dose: 2 mg/day. Cycle 6–12 months; FDA-approved for long-term use in appropriate patients. Some pair with Ipamorelin at bedtime.',
cycleLength: '3–12 months',
stack: 'Tesamorelin + Ipamorelin: GHRH + GHRP combination for comprehensive GH optimization. Particularly effective for visceral fat reduction vs other GHRH peptides.'
},
{
name: 'Thymosin Alpha-1',
aliases: ['Thymosin-α1', 'Tα1', 'Zadaxin', 'TA1'],
description: 'A 28-amino acid peptide naturally secreted by the thymus gland. FDA-approved in 35+ countries (as Zadaxin) for hepatitis B and C, HIV, and cancer immunotherapy. Acts as a master immune system modulator, enhancing both innate and adaptive immunity.',
halfLife: '~2 hours',
doseRange: '1.6 mg 2× per week (clinical standard)',
route: 'Subcutaneous',
mechanism: 'Activates dendritic cells, increases T-helper cell activity, stimulates NK cell production, and upregulates MHC class I/II expression. Modulates Toll-like receptor signaling. Also has antifungal and antiviral properties through direct mechanisms.',
protocols: 'Standard dose: 1.6 mg SC 2× per week. Acute immune support: 3.2 mg 2× per week for 4 weeks. Preventive protocols: 1.6 mg once weekly. Clinical courses typically run 6 months.',
cycleLength: '4–24 weeks depending on indication',
stack: 'Immune optimization stack: Thymosin Alpha-1 + Epithalon + GHK-Cu. For post-viral recovery: TA1 + LL-37 + BPC-157. For cancer supportive care: combine with Cerebrolysin and NAD+.'
},
{
name: 'Tirzepatide',
aliases: ['Mounjaro', 'Zepbound', 'LY3298176', 'GIP/GLP-1 dual agonist'],
description: 'A dual GIP and GLP-1 receptor agonist that produced unprecedented weight loss results in Phase 3 SURPASS trials — up to 22.5% body weight reduction. FDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Surpasses semaglutide in most comparative analyses.',
halfLife: '~5 days (once-weekly dosing)',
doseRange: '2.5–15 mg/week SC (escalation over 20 weeks)',
route: 'Subcutaneous (weekly)',
mechanism: 'GIP receptor agonism: enhances insulin secretion, reduces glucagon, improves adipocyte insulin sensitivity, and has direct CNS effects on appetite. GLP-1 receptor: reduces hunger, slows gastric emptying. Dual mechanism produces superior outcomes vs GLP-1 alone.',
protocols: 'Dose escalation every 4 weeks: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg/week. Maintenance at tolerated dose (5–15 mg/week). Inject SC once weekly, any time of day.',
cycleLength: 'Long-term; gradual taper if stopping',
stack: 'Weight management: Tirzepatide + AOD-9604 + Lipo-C. Avoid combining with other GLP-1 agents. Add resistance exercise protocol for optimal body recomposition.'
},
{
name: 'VIP',
aliases: ['Vasoactive Intestinal Peptide', 'PHI-27', 'VIP neuropeptide'],
description: 'A 28-amino acid neuropeptide and hormone found throughout the nervous system, GI tract, and lungs. Potent vasodilator, bronchodilator, and immune modulator. Studied for inflammatory conditions, autism spectrum disorder, pulmonary hypertension, and CIRS (Chronic Inflammatory Response Syndrome).',
halfLife: '~1 minute in blood; intranasal effects last hours',
doseRange: '50 mcg intranasal per day (CIRS protocol); 2–4 mcg/kg IV',
route: 'Intranasal (most common) or Intravenous',
mechanism: 'Binds VPAC1 and VPAC2 receptors. Promotes bronchodilation and vasodilation. Inhibits pro-inflammatory cytokines (TNF-α, IL-6, IL-12). Protects against neuroinflammation. Regulates circadian rhythms via the SCN. Stimulates PACAP-dependent neuroprotection.',
protocols: 'CIRS/Shoemaker protocol: 50 mcg intranasal twice daily. Chronic inflammation: 50–200 mcg intranasal daily. IV protocols under physician supervision at 2–4 mcg/kg. Some cycle 2–4 weeks on/off.',
cycleLength: '4–12 weeks; can be long-term under guidance',
stack: 'Anti-inflammatory stack: VIP + BPC-157 + LL-37. For CIRS: VIP used as final step in Shoemaker protocol. Pairs with NAD+ for comprehensive inflammatory modulation.'
},
{
name: 'Wolverine',
aliases: ['BB blend', 'BPC+TB500 combo', 'Wolverine blend'],
description: 'A blend of BPC-157 (5 or 10 mg) and TB-500 (5 or 10 mg) combined in a single vial. Named for the fictional character\'s regenerative abilities. Provides both the local healing action of BPC-157 and the systemic repair properties of TB-500 in a convenient single injection.',
halfLife: 'BPC-157: ~4h; TB-500: ~24h',
doseRange: 'BB10 (10 mg total): 1 vial 1–2× weekly; BB20 (20 mg total): 1 vial weekly',
route: 'Subcutaneous',
mechanism: 'Combines BPC-157 (FAK-paxillin healing pathway, angiogenesis, NO modulation, GH receptor upregulation) with TB-500 (actin sequestration, stem cell mobilization, systemic anti-inflammation, VEGF-driven angiogenesis) for comprehensive tissue repair.',
protocols: '1 vial SC once or twice weekly. For active injury: twice weekly for 4 weeks, then once weekly for maintenance. Pre-surgical and post-surgical use: start 2 weeks before and continue 4 weeks after.',
cycleLength: '4–8 weeks for injury; ongoing for maintenance dosing',
stack: 'The foundational healing stack. Upgrade to "Glow" (add GHK-Cu) or "Klow" (add GHK-Cu + KPV) for more comprehensive protocols. Layer with GH peptides (CJC/Ipamorelin) for peak recovery.'
}
];
const DEFAULT_PEPTIDES = [
'5-amino-1mq','AICAR','AOD-9604','ARA-290','Adalank','Adamax','BPC-157',
'Cerebrolysin','CJC-1295','CJC-195/IPA','DSIP','Dihexa','Epithalon',
'GHK-CU','GhRIP','Glow','Glutathione','IGF-1 LR3','Ipamorelin','KPV',
'Kisspeptin','Klow','LL-37','Lipo-C','MOTS-C','NAD+','Oxytocin',
'PE-22-28','PT-141','Pinealon','Retatrutide','SS-31','SLU-PP-332',
'Semax','Selank','Sermorelin','TB-500','Tesamorelin','Thymosin Alpha-1',
'VIP','Wolverine'
];
const ORDER_STATUSES = ['Ordered','Processing','Shipped','In Transit','Delivered','Stored','Used','Cancelled'];
const ORDER_STATUS_BADGE = {
'Ordered': 'badge-info',
'Processing': 'badge-pending',
'Shipped': 'badge-info',
'In Transit': 'badge-info',
'Delivered': 'badge-done',
'Stored': 'badge-done',
'Used': 'badge-done',
'Cancelled': 'badge-pending'
};
let _orderFilter = '';
let _orderFormId = undefined;
// ── Task 9: Auth ──────────────────────────────────────────────────────────────
function renderAuth(mode) {
const logo = `
PeptideOS
Research tracking platform
`;
if (mode === 'login') {
document.getElementById('authScreen').innerHTML = `
`;
} else if (mode === 'reset') {
// Capture token in closure — never interpolate into HTML attribute
const token = new URLSearchParams(window.location.search).get('token') || '';
document.getElementById('authScreen').innerHTML = `
${logo}
`;
// Bind via closure so token never touches the DOM
document.getElementById('resetSubmitBtn').onclick = () => doReset(token);
}
}
async function doLogin() {
const email = document.getElementById('authEmail').value.trim();
const pass = document.getElementById('authPass').value;
const err = document.getElementById('authErr');
err.textContent = '';
if (!email || !pass) { err.textContent = 'Email and password are required.'; return; }
try {
await App.login(email, pass);
await App.loadAll();
showApp();
renderAllTabs();
} catch (e) {
err.textContent = e.message || 'Login failed. Check credentials and try again.';
}
}
async function doRegister() {
const email = document.getElementById('authEmail').value.trim();
const pass = document.getElementById('authPass').value;
const confirm = document.getElementById('authPassConfirm').value;
const tos = document.getElementById('checkTos').checked;
const disc = document.getElementById('checkDisclaimer').checked;
const err = document.getElementById('authErr');
err.textContent = '';
if (!tos) { err.textContent = 'You must agree to the Terms of Service and Privacy Policy.'; return; }
if (!disc) { err.textContent = 'You must acknowledge this app is for personal tracking only.'; return; }
if (pass.length < 8) { err.textContent = 'Password must be at least 8 characters.'; return; }
if (pass !== confirm) { err.textContent = 'Passwords do not match.'; return; }
try {
await App.register(email, pass);
await App.loadAll();
showApp();
renderAllTabs();
} catch (e) {
err.textContent = e.message || 'Registration failed. Please try again.';
}
}
async function doForgot() {
const email = document.getElementById('authEmail').value.trim();
const err = document.getElementById('authErr');
err.textContent = '';
if (!email) { err.textContent = 'Please enter your email.'; return; }
try {
await API.post('/auth/forgot', { email });
document.getElementById('forgotSuccess').style.display = 'block';
} catch (e) {
err.textContent = e.message || 'Something went wrong. Please try again.';
}
}
async function doReset(token) {
const pass = document.getElementById('authPass').value;
const confirm = document.getElementById('authPassConfirm').value;
const err = document.getElementById('authErr');
err.textContent = '';
if (pass.length < 8) { err.textContent = 'Password must be at least 8 characters.'; return; }
if (pass !== confirm) { err.textContent = 'Passwords do not match.'; return; }
try {
await API.post('/auth/reset', { token, password: pass });
renderAuth('login');
} catch (e) {
err.textContent = e.message || 'Reset failed. The link may have expired.';
}
}
// ── Task 10: Today ─────────────────────────────────────────────────────────────
function calcStreak(logs) {
let streak = 0;
const today = new Date();
today.setHours(0, 0, 0, 0);
for (let i = 0; i < 365; i++) {
const d = new Date(today.getTime() - i * 86400000);
const ds = ymd(d);
const hasLog = logs.some(l => l.taken_at && l.taken_at.slice(0, 10) === ds);
if (hasLog) streak++;
else if (i > 0) break;
}
return streak;
}
function calcBestStreak(logs) {
if (!logs.length) return 0;
const days = [...new Set(logs.map(l => l.taken_at?.slice(0, 10)).filter(Boolean))].sort();
let best = 0, current = 0, prev = null;
for (const day of days) {
if (prev) {
const diff = (new Date(day) - new Date(prev)) / 86400000;
current = diff === 1 ? current + 1 : 1;
} else {
current = 1;
}
best = Math.max(best, current);
prev = day;
}
return best;
}
function renderToday() {
const { planner, logs, settings } = App.getData();
const today = new Date();
const todayYmd = ymd(today);
const todayDay = today.getDay();
const todayPlans = planner.filter(p => p.day === todayDay);
const todayLogs = logs.filter(l => l.taken_at && l.taken_at.slice(0, 10) === todayYmd);
const doneCount = todayPlans.filter(p => planMatched(p, todayLogs)).length;
const pendingCount = todayPlans.length - doneCount;
const streak = calcStreak(logs);
const pct = todayPlans.length ? Math.round((doneCount / todayPlans.length) * 100) : 0;
let doseRows = '';
if (todayPlans.length === 0) {
doseRows = '
Add planner items in Settings.
';
} else {
for (const plan of todayPlans) {
const done = planMatched(plan, todayLogs);
const timeStr = plan.time || '';
doseRows += `